Multiomics Services Market Size, Share & Trends Analysis Report By Service (Research, Data Analysis), By Type (Single-cell Multiomics, Bulk Multiomics), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

Multiomics Services Market Growth & Trends

The global multiomics services market size is projected to reach USD 4.72 billion by 2033, growing at a CAGR of 17.41% from 2025 to 2033, according to a new report by Grand View Research, Inc. The multiomics services industry is witnessing accelerated growth, driven by the increasing demand for integrated biological data to enable precision medicine, advanced diagnostics, and systems biology research. As the need to understand complex biological mechanisms intensifies, multiomics approaches combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics are becoming essential tools for comprehensive biomarker discovery, disease stratification, and therapeutic development.

Pharmaceutical and biotechnology companies, research institutions, and clinical laboratories increasingly leverage multiomics platforms to gain deeper insights into disease pathways, therapeutic targets, and patient-specific responses. Strategic collaborations, rising R&D investments, and technological convergence catalyze innovation in multiomics service offerings while enhancing data integration and interpretability across diverse omics layers.

The growing adoption of multiomics in oncology, immunology, neurology, and infectious disease research further fueled the market's expansion. As regulatory frameworks around data quality, privacy, and clinical validation tighten, service providers invest in robust quality control systems, secure data management solutions, and AI-driven analytics to meet evolving customer and compliance needs. Multiomics services are reshaping the future of translational medicine and individualized healthcare by offering holistic views of biological systems and disease progression.

With the rapid evolution of omics technologies and the growing demand for precision insights, the multiomics services market is positioned to become a cornerstone of next-generation biomedical innovation and global health transformation.

Multiomics Services Market Report Highlights

• The research services segment accounted for the largest market revenue share in 2024. This leadership derives from their foundational role in supporting preclinical studies, mechanistic research, and early-stage drug discovery. As multiomics approaches become integral to understanding complex disease biology, academic and commercial research demand continues to rise.
• The bulk multiomics segment accounted for the largest market revenue share in 2024, owing to its widespread adoption in large-scale studies and established workflows in genomics, transcriptomics, and proteomics. These approaches are widely used in population-level biomarker discovery, disease profiling, and target validation. Advances in single cell sequencing technologies continue to drive adoption across oncology, immunology, and neuroscience research.
• The drug discovery & development segment led the market with the largest revenue share of 35.45% in 2024, driven by the growing need for integrated data to accelerate target identification and streamline R&D. However, the synthetic biology segment is expected to grow at the fastest CAGR of 19.40% over the forecast period.
• The pharmaceutical and biotechnology segment accounted for the largest market revenue share in 2024. These organizations integrate multiomics into R&D workflows to accelerate precision drug development, companion diagnostics, and therapeutic optimization. Increasing collaborations with contract research organizations (CROs) and multiomics platform providers support this segment.
• North America dominated the market with the largest revenue share of 40.13% in 2024. This is attributed to advanced healthcare infrastructure, strong genomics research funding, and early adoption of omics technologies. However, Asia Pacific is expected to grow at the highest CAGR of 19.62% over the forecast period.
• In January 2025, NVIDIA announced strategic partnerships with IQVIA, Illumina, Mayo Clinic, and Arc Institute to revolutionize genomics, drug discovery, and healthcare. The initiatives focus on developing AI agents to expedite clinical trials, AI models for drug discovery and digital pathology, and physical AI robots for surgery and patient monitoring.